UNSPSC 51294204: Indeloxazine

This classification denotes an antidepressant agent with the molecular formula C14H17NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 834M09R1KM, chemically known as (r,s)-2-(7-indenyloxymethyl)morpholin but generally known as indeloxazine, which bears US NIH Compound Identifier 3704. European Medicines Agency schedules Indeloxazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08172MIG. The term INDELOXAZINE is an International Non-Proprietary Name.

UNSPSC 51294204 Indeloxazine, a Commodity code, covers pharmaceutical products and related distribution systems that state and local governments procure for community health, emergency response, and pharmaceutical benefit programs. Recent opportunities under this code show state and local agencies buying naloxone and drug deactivation systems for public health initiatives, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription programs to improve cost management and supply chain efficiency. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving participating state and local government facilities. The procurement mix ranges from straightforward competitive bids for specific quantities of emergency medications to complex RFPs for statewide or multi-state generic pharmaceutical contracts requiring manufacturer partnerships with authorized wholesalers and compliance with FDA, cGMP, and Drug Supply Chain Security Act standards.

Activity under this code concentrates in Florida and Minnesota, with Texas state-level involvement in exploratory market research. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive bid basis with a response deadline of July 26, 2023, requiring quarterly deliveries to its Community Health Building in Sanford. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP in January 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products across multiple state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information in April 2026 (HHS0017013) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement activity in that state.